THE ROLE OF URIC ACID IN THE PROGRESSION OF CKD Mehmet Kanbay, Istanbul, Turkey
|
|
- Ferdinand Banks
- 6 years ago
- Views:
Transcription
1 THE ROLE OF URIC ACID IN THE PROGRESSION OF CKD Mehmet Kanbay, Istanbul, Turkey Chairs: Gerjan Navis, Groningen, The Netherlands Kamil Serdengecti, Istanbul, Turkey Dr. M. Kanbay Division of Nephrology Department of Medicine Istanbul Medeniyet University School of Medicine Istanbul, Turkey Slide 1 Dear Chairs. Slide 2
2 As you all know, uric acid may cause kidney disease in three forms by causing nephrolithiasis, by precipitating in tubules mostly seen in malignancy and by causing some metabolic changes, after that it may cause progression of kidney disease. My talk will focus on this, first I will discuss how uric acid may cause the progression of kidney disease and whether it has a role in the development of hypertension and the last part of my talk will focus on whether lowering uric acid therapy should be a target therapy for CKD or not. Slide 3 Uric acid is an end product of purine, it occurs by xanthine oxidoreductase enzyme, some factors may increase uric acid levels in CKD. These are reduced GFR, diuretic use, increased renal vascular incidence and co-existence of insulin resistance also. Slide 4
3 We still do not know which one is the chicken and which one is the egg. There are two hypotheses. Slide 5 Really uric acid may have a role in the development of cardiovascular disease, CKD, and hypertension
4 Slide 6 or may not have a role in the development of cardiovascular disease, CKD, hypertension but might be associated. Slide 7
5 Here one of the most important difficulties is to relate uric acid, as a pathogenic factor, in hypertension, cardiovascular disease, CKD is the abundance of other potential confounders. Slide 8
6 But if we show an association between uric acid levels and hypertension in observational studies, after that, if we show it in clinical basic experimental studies that high uric acid may cause increased blood pressure, may have a role in the progression of CKD and whether if it causes some hemodynamic changes especially in the kidney. Also in experimental studies if it is shown the beneficial effect of lowering uric acid and if proven at the end of this research in human studies, we may say that high uric acid levels might have a role or is an independent factor for hypertension, cardiovascular disease and also for CKD. Slide 9 In this review, we included all studies with long-term follow-up and patients with this study higher than 100. Slide 10
7 As you see here, in almost all studies showed that high uric acid level predicts the development of hypertension in the long-term follow-up even after adjusted for well-known established risk factors for hypertension such as age, BMI, family history, and alcohol intake. Slide 11 A recent meta-analysis investigated this association, they included 18 prospective studies, more than 55,000 subjects and they showed an independent risk factor for development of hypertension. They also found that the overall risk for incident hypertension increased 13% per 1 mg/dl increase in serum uric acid levels. Slide 12
8 So, in the light of this study we may speculate that baseline high uric acid levels might predict the development of hypertension. Slide 13 What about the association between uric acid level and the kidney disease progression? Slide 14
9 Yes, some big studies say that high uric acid level might be an independent risk factor for kidney disease progression. Slide 15 However, some other big studies say that no, it might be associated but not independent from other established risk factors. So, there are contradictory results here. Slide 16
10 As you all know, at the beginning of the 19th century the prevalence of hypertension was less than 10%. Nowadays it is higher than 30%. In the same line as the other Slide 17 is that cardiac partner, we know it well, uric acid level is going up decade after decade
11 because of this some epidemiologists speculate that the higher uric acid level might have an additional risk for the increased incidence of hypertension. Slide 18 From the USA, Daniel Feig and Richard Johnson did a study, they included 125 adolescent population with hypertension. They aimed to look at the association between uric acid level and primary or essential hypertension. Slide 19
12 They showed that patients with primary hypertension have significantly higher uric acid levels compared to secondary hypertension, white coat hypertension and the control group. Slide 20 Another study from our group, we investigated the association between the diurnal blood pressure variation and uric acid level and they included 112 newly diagnosed primary hypertensive subjects. We performed in all subjects ABPM measurements Slide 21
13 and we showed that if patients have primary hypertension, they significantly have higher uric acids levels. It is also true for CRP levels. If these hypertensive subjects are non-dippers, they also have significantly higher uric acid levels, CRP levels compared to dipper hypertensive subjects. Slide 22 Also we showed that uric acid also has a positive correlation between CRP levels so we may also speculate that in the light of this study high uric acid levels might have a role also in the development of high inflammation. Slide 23
14 What about the role of uric acid in kidney disease? I'll first mentioned some experimental studies and then clinical studies. Slide 24 As I mentioned before uric acid is an end product of purine. In other mammals, there is an enzyme that degrades uric acid to Allantoin by inhibiting this enzyme with Oxonic acid and rats become hyperuricemic. Slide 25
15 Firstly, Sánchez-Lozada from Florida showed that high uric acid increases glomerular pressure and if these are treated with allopurinol, glomerular pressure becomes normal. Slide 26 In another study from the same group, they also showed that high uric acid level increases glomerular size in rats and if they're treated with allopurinol, also glomerular size becomes normal. Slide 27
16 Another study showed that hyperuricemic rats' glomerulus become sclerotic after several weeks. Slide 28 This is very important study by Kang they investigated the role of uric acid in kidney disease progression. They had four groups; one sham, one CKD group, one hyperuricemic CKD group and the other one treated with allopurinol.
17 Slide 29 They showed that the rats with hyperuricemia have significantly higher systolic blood pressure, higher creatinine levels, higher proteinuria and these rats have mostly higher glomerulosclerosis. But if these rats treated with allopurinol, as you see here, there are significant improvements in all four parameters. Slide 30
18 Also high uric acid increases renin expression, also increases renin release. If these rats treated with allopurinol expression and release of renin decreases Slide 31 and also increases oxidative stress, inflammation, angiotensin 2 levels Slide 32
19 and at the same time also decreases NO levels. Slide 33 Also from Richard Johnson's group, they did a study, they showed that high uric acid level causes an increased blood pressure in rat studies. If these rats treated with allopurinol, as you see here, blood pressure going down and down. Slide 34
20 So in the light of these experimental studies we may speculate that high uric acid may have a role in the development of hypertension and chronic kidney disease progression. What about clinical studies? In this study from our group, we investigated the effect of treatment of hyperuricemia with allopurinol on blood pressure, kidney function and proteinuria in patients with normal kidney function. Slide 35 They included 48 hyperuricemic and 21 normal uricemic patients and they followed all subjects for 3 months. Slide 36
21 In the end Slide 37 as you see here, there isn't any significant change in the control group. Slide 38
22 However, if you look at the allopurinol group, you can see that there is a significant improvement in kidney function, CRP levels and also in blood pressure. Slide 39 Another study from Spain, this is a very important and interesting study. Slide 40
23 They aimed to look at the effect of allopurinol on kidney disease progression, cardiovascular events and the rate of hospitalization. They had 113 CKD subjects with stage 3 and they treated 50 of these patients with allopurinol, others recruited as control group. For baseline parameters, there isn't any significant difference between the two groups. Slide 41
24 You can see here Slide 42 that after 24 months follow-up in the control group you can see the decrease in GFR values although it is not significant. But in the allopurinol group you can see an increase even if it is not significant, you can see the decrease in GFR values in the control group, you can see an increase in the allopurinol group. Slide 43
25 They compared the delta change between two groups and it becomes significant. What about cardiovascular events? Slide 44 In the allopurinol treated group, the number of the cardiovascular event is significantly lower compared to the control group. Slide 45
26 In the light of this study, we may conclude that allopurinol treatment slows the progression of kidney disease, decreases cardiovascular events and also decreases inflammation in patients with stage 3. Slide 46 Another in an interesting study form Daniel Feig form Texas, they looked at the effect of allopurinol on blood pressure in a newly diagnosed essential hypertensive subject. Slide 47
27 This is a randomized double-blinded placebo controlled design. They had 30 children, all were pharmacologically naïve Slide 48 and in the end in subjects whose uric acid levels was below 5 mg/dl in these subjects 86% of these subjects became normotensive without any antihypertensive treatment. However, in the control group only one subject became normotensive. Slide 49
28 Also there is a meta-analysis published in the journal of clinical hypertension. They concluded 10 studies and they looked at the effect of allopurinol treatment Slide 50 on blood pressure and you can see here, that allopurinol treatment has a beneficial effect on lowering the systolic blood pressure as well. Slide 51
29 Also allopurinol treatment has a beneficial effect on endothelial function in many of the studies. So also it has a beneficial effect on endothelial function also. Slide 52 In summary, high uric acid increases angiotensin 2 levels, decreases NO levels, increases
30 oxidative stress mostly by NADPH oxidase activity and also it causes some muscular smooth muscle cell changes. In the end it causes microvascular disease and because of this hypertension may develop. So if --- of high uric acid level before it causes micro muscular disease we may postpone the development of hypertension or prevent the development of hypertension also we may have a beneficial or additional effect on kidney disease progression. Slide 53 Also hyperuricemia has adverse effects on the cardiovascular system by increasing the activation of the renin angiotensin system, it also causes cardiovascular smooth muscle cell proliferation and decreases NO levels and also has some adverse effects on brain. Also as I showed before treatment of hyperuricemia has beneficial effects on blood pressure, kidney function, inflammation and endothelial function. Slide 54
31 So hyperuricemia is an independent risk factor or might be an independent risk factor for the development of hypertension, might have a role in kidney disease progression. We still do not know, hyperuricemia might be a prognostic marker like CRP or might be a pathogenic factor for this disease, we still do not know. Also uric acid might be a strong surrogate marker to predict the development of future hypertension and lowering uric acid agents might be defined as a new antihypertensive or cardiorenal protective drug. Also in the light of these studies, we may speculate that hyperuricemia might be a new cardiorenal toxin. Slide 55 Which populations should we treat? We still do not know the correct answer to this. But in at risk populations uric acid lowering therapies might be associated with lower blood pressure, Slide 56
32 lower rate of GFR loss and reduce the rate of the development of cardiovascular events. But do not forget we do not have enough evidence to recommend to treat hyperuricemic patients. Because these studies are small studies the quality of these studies is moderate, the followup period relatively short and because of this we still need strong well-designed with longterm follow-up studies. Slide 57 Thank you for your attention. Slide 58
33 Chairman: Thank you doctor Kanbay for a beautiful overview. Question: In chronic kidney disease patients with non-symptomatic hyperuricemia, what's your recommended uric acid level above which we have to treat hyperuricemia? Prof. Kanbay: We still do not know the correct answer to this. In my opinion, one measurement of uric acid level is not enough to give a decision to whether these patients are hyperuricemic or not. In the current knowledge the indications for treatment of hyperuricemia is higher than 10. But in my clinical practice mostly I have treated patients higher than 8 but this is my opinion. Question: I have an additional question for you. Let's say uric acid is mainly a reason for concern in kidney patients and we have a lot of questions on that. In proteinuric patients, at least, we have to reduce dietary sodium to get the proteinuria down or RAS blockade and what happens is that the uric acid goes up very much. Often gout is something that prevents me from achieving adequate volume control in the patients. Could you comment on that? Prof. Kanbay: In my opinion, there might be a threshold for limiting the sodium level. We do not know after which level sodium restriction causes an increase in uric acid levels. We do basic research and also clinical research and we still do not know the correct answer to your question. But in my opinion, sodium restriction should be the most important part because we have enough evidence that high sodium level is more dangerous than uric acid level so we may restrict. But in my clinical practice, mostly I don't see too much hyperuricemia after sodium restriction. It causes slight increases. Chairman: Ok thank you. Well then, if there are no more questions we thank again the speakers and also the audience for their participation and good luck for the rest of the congress. Thank you.
Dr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.
The uric acid dilemma: causal risk factor for hypertension and CKD or mere bystander? Mehmet Kanbay, Istanbul, Turkey Chairs: Anton H. van den Meiracker, Rotterdam, The Netherlands Claudia R.C. Van Roeyen,
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationFructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationA study to assess relationship between Uric Acid and Blood pressure among patients attending tertiary care hospital in Central Gujarat
ORIGINAL ARTICLE A study to assess relationship between Uric Acid and Blood pressure among patients attending tertiary care hospital in Central Gujarat Meenakshi Shah 1, Varsha Godbole 2, Upesh Parmar
More informationProf. Michel Jadoul Cliniques universitaires St-Luc Université Catholique de Louvain Brussels, Belgium. Slide 1
Phosphate and cardiovascular disease beyond CKD: is phosphate a new cholesterol? Michel Jadoul, Brussels, Belgium Chairs: Pablo Urena Torres, Saint-Ouen, France Carmine Zoccali, Reggio Calabria, Italy
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationAllopurinol Against Progression of Chronic Kidney Disease
KIDNEY DISEASES Allopurinol Against Progression of Chronic Kidney Disease Sima Golmohammadi, 1 Afshin Almasi, 2 M Manouchehri, 1 Hamid Reza Omrani, 1 Mohammad Reza Zandkarimi 3 Original Paper 1 Department
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationJMSCR Vol 05 Issue 04 Page April 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.19 Original Research Article A Study on Serum
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More informationDIABETES AND YOUR KIDNEYS
DIABETES AND YOUR KIDNEYS OR AS WE CALL IT DIABETIC NEPHROPATHY The latest guidelines to keep you safe, healthy, fit, and out of danger from needing dialysis A UCLA HEALTH EDUCATIONAL SEMINAR Ramy M. Hanna
More informationCAN WE PREDICT THE RISK FOR ADVERSE EVENTS? Andrzej Wiecek, Katowice, Poland
CAN WE PREDICT THE RISK FOR ADVERSE EVENTS? Andrzej Wiecek, Katowice, Poland Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Andrzej Więcek Departm ent of Nephrology,
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationHyperurikaemie - nur Gicht oderauch kardio-renales Risiko?
9. November 2017 Hyperurikaemie - nur Gicht oderauch kardio-renales Risiko? PD Dr. Bernhard Hess Innere Medizin & Nephrologie NierensteinZentrum Zürich Hirslanden Kliniken Im Park & Hirslanden, Zürich
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationProf. Sandrine Florquin Department of Pathology Academic Medical Center University of Amsterdam Amsterdam, The Netherlands. Slide 1.
Interleukin 17 in renal biopsies as risk factor for progression Sandrine Florquin, Amsterdam, The Netherlands Chairs: Mohamed R. Daha, Leiden, The Netherlands Pierre Ronco, Paris, France Prof. Sandrine
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationStudy of Serum Uric Acid Level in Adolescents Who Were Born Preterm
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 14, Number 3 (2018) pp. 193-197 Research India Publications http://www.ripublication.com Study of Serum Uric Acid Level in
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationGout. Clinical features Most commonly affects middle-aged males. It is an acute and usually relapsing selflimiting
Gout Gout is a syndrome caused by an inflammatory response to the formation of monosodium urate monohydrate crystals which develop secondary to hyperuricemia. Acute and chronic forms are recognized. Hyperuricemia
More informationANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada
ANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Patrick S. Parfrey Division
More informationLow-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease
Nephrol Dial Transplant (2012) 27: 608 612 doi: 10.1093/ndt/gfr223 Advance Access publication 25 May 2011 Original Articles Low-fructose diet lowers blood pressure and inflammation in patients with chronic
More informationDr.Nahid Osman Ahmed 1
1 ILOS By the end of the lecture you should be able to Identify : Functions of the kidney and nephrons Signs and symptoms of AKI Risk factors to AKI Treatment alternatives 2 Acute kidney injury (AKI),
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationCLINICIAN INTERVIEW A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY. Interview with Ralph Rabkin, MD
A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY Interview with Ralph Rabkin, MD Dr Rabkin is Professor of Medicine, Emeritus, Active, at Stanford University School of Medicine, Stanford,
More informationKrediet slide di 18
1 di 18 Assessment of fluid status in PD patients Raymond T. Krediet, Amsterdam, Netherlands Chairs:Walther H. Boer, Utrecht, The Netherlands F. Fevzi Ersoy, Antalya, Turkey Prof. Raymond T. Krediet DDivision
More informationProf. Isabelle Six INSERM Unit 1088 Jules Verne University of Picardie Amiens, France. Slide 1. Slide 2
Effects of phosphate on vascular function New insights Isabelle Six, Amiens, France Chairs: Griet Glorieux, Ghent, Belgium Alberto Ortiz, Madrid, Spain Prof. Isabelle Six INSERM Unit 1088 Jules Verne University
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationmtor inhibitors lights and shadows Giuseppe Grandaliano, Foggia, Italy Chairs: Turgay Arinsoy, Ankara, Turkey Josep M. Grinyo, Barcelona, Spain
mtor inhibitors lights and shadows Giuseppe Grandaliano, Foggia, Italy Chairs: Turgay Arinsoy, Ankara, Turkey Josep M. Grinyo, Barcelona, Spain Prof. Giuseppe Grandaliano Nephrology Department Faculty
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationANAEMIA MANAGEMENT: HOW AND WHY DOES ERBP DIFFER FROM KDIGO Francesco Locatelli, Lecco, Italy
ANAEMIA MANAGEMENT: HOW AND WHY DOES ERBP DIFFER FROM KDIGO Francesco Locatelli, Lecco, Italy Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Francesco Locatelli
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationProf. Rosanna Coppo Director of the Nephrology, Dialysis and Transplantation Department Regina Margherita Hospital Turin, Italy. Slide 1.
ROLE OF PATHOLOGY AND CLINICAL FEATURES IN PREDICTING PROGRESSION OF IGA NEPHROPATHY: RESULTS FROM THE ERA-EDTA RESEARCH VALIGA Rosanna Coppo, Turin, Italy Chairs: François Berthoux, Saint-Etienne, France
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationPrognosis in CKD Can we do anything about it? Rodney D Gilbert
Prognosis in CKD Can we do anything about it? Rodney D Gilbert A diagnosis of end stage renal failure implies what degree of loss of life expectancy? A. 10% B. 20% C. 30% D. 40% E. 50% F. 60% 38% 22% 16%
More informationProf. Franco Ferrario Nephropathology Unit Department of Pathology San Gerardo Hospital Università Milan Bicocca Monza, Italy.
The role of repeated biopsies in the management of Lupus Nephritis Franco Ferrario, Milan, Italy Chairs: David Jayne, Cambridge, UK Vladimir Tesar, Prague, Czech Republic Prof. Franco Ferrario Nephropathology
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationKDIGO Controversies Conference on Blood Pressure in CKD
KDIGO Controversies Conference on Blood Pressure in CKD September 7-10, 2017 Edinburgh, Scotland Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationHypertension Update. ACOI 2018 John Prior
Hypertension Update ACOI 2018 John Prior Disclosures Nothing to declare Hypertension - Introduction US population incidence 30% and growing due to an aging and increasingly obese population Poorly controlled
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationPRE-DIALYSIS CARE IN CHRONIC KIDNEY DISEASE PATIENTS DR O. A ADEJUMO MBBS, FWACP, FMCP
PRE-DIALYSIS CARE IN CHRONIC KIDNEY DISEASE PATIENTS DR O. A ADEJUMO MBBS, FWACP, FMCP OUTLINE INTRODUCTION BURDEN OF CKD DEFINITION OF PRE-DIALYSIS CARE (PDC) GOALS OF PDC IN CKD COMPONENTS OF PDC ADVANTAGES
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationObesity mediated hypertension and renal dysfunction
Obesity mediated hypertension and renal dysfunction Gergely Bodor Marion Hervouet Nicky Honnef Mariarosaria Malgadi Julie Robert Tutor: Pr Alina Parvu Objectives 1. Introduction 2. Renal structural and
More informationInsidie del binomio iperuricemia e rischio CV
Insidie del binomio iperuricemia e rischio CV Claudio Borghi, FESC, FAHA Department of Medical and Surgical Sciences University of Bologna, Bologna, Italy Claudio Borghi Potential conflicts of interest
More informationProf. David Wheeler Centre for Nephrology Royal Free Campus University College London Medical School London, UK. Slide 1
LDL-CHOLESTEROL AND CV RISK IN CKD: EPIDEMIOLOGY VS. CLINICAL TRIALS David Wheeler, London, UK Chairs: Maurice Laville, Lyon, France Erling B. Pedersen, Holstebro, Denmark Prof. David Wheeler Centre for
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationMedical therapies to reduce chronic kidney disease progression and cardiovascular risk: uric acid-lowering agents
Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: uric acid-lowering agents Date written: July 2012 Author: Richard Phoon, David Johnson GUIDELINES a. We suggest that
More informationQuality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care
Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Intermediate
More informationThe Association of Pediatric Obesity with Nocturnal Non-Dipping on. 24-Hour Ambulatory Blood Pressure Monitoring. Ian Macumber.
The Association of Pediatric Obesity with Nocturnal Non-Dipping on 24-Hour Ambulatory Blood Pressure Monitoring Ian Macumber A thesis submitted in partial fulfillment of the requirements for the degree
More informationElevated Serum Creatinine, a simplified approach
Elevated Serum Creatinine, a simplified approach Primary Care Update Creighton University School of Medicine. April 27 th, 2018 Disclosure Slide I have no disclosures and have no conflicts with this presentation.
More informationCLINICAL BIOCHEMISTRY 6 PLASMA PROTEINS AND PATHOLOGICAL IMPLICATIONS OF THEIR IMBALANCE
LINIAL BIOHEMISTRY 6 PLASMA PROTEINS AND PATHOLOGIAL IMPLIATIONS OF THEIR IMBALANE DISTURBANES OF PROTEIN METABOLISM NPN result from the metabolism of aminoacids, proteins, nucleic acids 2.3.1. UREA (75%
More informationStudy of Serum Uric Acid Level in Hypertension
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 4 Ver. VI (April. 2017), PP 69-73 www.iosrjournals.org Study of Serum Uric Acid Level in Hypertension
More informationProf. Michael Joannidis Medical Intensive Care and Emergency Unit Department of Internal Medicine Medical University Innsbruck Innsbruck, Austria
1 di 27 Prevention of AKI: experimental promises and clinical realities Michael Joannidis, Innsbruck, Austria Chairs:Norbert Lameire, Ghent, Belgium Gert Mayer, Innsbruck, Austria Prof. Michael Joannidis
More informationFaculty. Disclosures. Learning Objectives. Definitions. Definitions (cont) The Role of the Kidney in Cardiometabolic Disease
Faculty The Role of the Kidney in Cardiometabolic Disease Christian W. Mende, MD, FACP, FACN, FASN, FASH Clinical Professor of Medicine University of California at San Diego San Diego, California Disclosures
More informationWHY DO WE NEED AN EXCRETORY SYSTEM? Function: To eliminate waste To maintain water and salt balance To maintain blood pressure
EXCRETORY SYSTEM WHY DO WE NEED AN EXCRETORY SYSTEM? Function: To eliminate waste To maintain water and salt balance To maintain blood pressure These wastes include: Carbon dioxide Mostly through breathing
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationPotassium secretion. E k = -61 log ([k] inside / [k] outside).
1 Potassium secretion In this sheet, we will continue talking about ultrafiltration in kidney but with different substance which is K+. Here are some informations that you should know about potassium;
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationIntroduction to Clinical Diagnosis Nephrology
Introduction to Clinical Diagnosis Nephrology I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of Florida College
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationUric acid in Chronic Heart Failure; Correlation with Prognostic Markers
Ibnosina J Med BS 143 ARTICLE Uric acid in Chronic Heart Failure; Correlation with Prognostic Markers Fathia Ehmouda 1, Hamid Elbrasai 2, Ali M Elneihoum 1 1 Department of Medicine, 7 th October University
More informationProtecting the kidneys in lupus nephritis
Review Protecting the kidneys in lupus nephritis Kidney involvement is common in systemic lupus erythematosus. The inciting event in lupus nephritis is immune complex accumulation in the kidneys. While
More informationCHRONIC KIDNEY DISEASE WHY WOMEN MAY BE AT RISK?
CHRONIC KIDNEY DISEASE WHY WOMEN MAY BE AT RISK? Dr. Judy A Geissler, DNP, APNP, FNP-BC, CNN Vascular Access Advanced Practice Provider Employer- Medical College of Wisconsin No financial disclosures Barbara
More informationRENAL GRAND ROUNDS. Vitamin D- Beyond the bone. Dr Krishna Pakkivenkata. 9 th April 2010.
RENAL GRAND ROUNDS Vitamin D- Beyond the bone Dr Krishna Pakkivenkata. 9 th April 2010. Brief history Secosteroid. 1920 s-exposure to sunlight prevented rickets. 1936- structure of Vit D was discovered.
More informationEARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland
EARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Julio Pascal Hospital del Mar Nephrology Department Barcelona,
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationBBC LEARNING ENGLISH 6 Minute English Diabetes
BBC LEARNING ENGLISH 6 Minute English Diabetes NB: This is not a word-for-word transcript Hello and welcome to 6 Minute English. I'm And I'm. Can you pass me my drink,? Cola,? That's very unhealthy. You
More informationChronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham
Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure
More informationUrea cycle: Urea cycle is discovered by Krebs andhanseleit(1932).
Urea cycle: Urea cycle is discovered by Krebs andhanseleit(1932). Urea cycle is the removal of excess of NH2 derived from amino acids catabolism in the tissues and excreted in urine. Site of synthesis:
More informationBlood Pressure Treatment in 2018
Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationCase presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg
GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies
More informationUnderstanding Acute Kidney Injury and Its Impact
Understanding Acute Kidney Injury and Its Impact Recorded on: March 7, 2013 Chi-Yuan Hsu, M.D., M.S. Chief of the Division of Nephrology, UCSF Department of Medicine UCSF Medical Center Raymond Hsu, M.D.
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More information1. Staging of CKD based on blood creatinine concentration
1. Staging of CKD based on blood creatinine concentration Staging is undertaken following diagnosis of chronic kidney disease (CKD) in order to facilitate appropriate treatment and monitoring of the patient.
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More information